Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.

類似資料

• Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease
  著者:: Ulrika Andersson, 等
  出版事項: (2004-08-01)
• NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
  著者:: Jeyakumar, M, 等
  出版事項: (2004)
• N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
  著者:: Andersson, U, 等
  出版事項: (2000)
• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal sandhoff diseased mice
  著者:: Baek, R, 等
  出版事項: (2004)
• N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
  著者:: Baek, R, 等
  出版事項: (2008)